Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 9, 2013, Pages 1482-1488

  Renouf, Daniel J ^a,b   Zhai, Rihong ^c   Sun, Bin ^a   Xu, Wei ^a   Cheung, Winson Y ^b   Heist, Rebecca S ^d   Kulke, Matthew H ^e   Cescon, David ^a   Asomaning, Kofi ^c   Marshall, Ariella L ^c   Li, Su ^c   Christiani, David C ^c,d   Liu, Geoffrey ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Esophageal cancer; GERD; MDM2; P53; Polymorphisms

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ESOPHAGEAL CANCER; GERD; MDM2; P53; POLYMORPHISMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84897619011     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12286     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int. J. Epidemiol. 2000; 29: 645-654.
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
4. Lagergren J, Lagergren P. Oesophageal cancer. BMJ 2010; 341: c6280.
5. Sundelof M, Ye W, Dickman PW, Lagergren J. Improved survival in both histologic types of oesophageal cancer in Sweden. Int. J. Cancer 2002; 99: 751-754.
6. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999; 340: 825-831.
7. Das KM, Kong Y, Bajpai M etal. Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: a novel in vitro model. Int. J. Cancer 2011; 128: 274-282.
8. Maley CC, Rustgi AK. Barrett's esophagus and its progression to adenocarcinoma. J. Natl Compr. Canc. Netw. 2006; 4: 367-374.
9. Audrezet MP, Robaszkiewicz M, Mercier B etal. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Hum. Mutat. 1996; 7: 109-113.
10. Keswani RN, Noffsinger A, Waxman I, Bissonnette M. Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2006; 15: 1243-1249.
11. Jin S, Levine AJ. The p53 functional circuit. J. Cell Sci. 2001; 114 (Pt 23): 4139-4140.
12. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999; 59: 1-7.
13. Bond GL, Hu W, Bond EE etal. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
14. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005; 65: 5481-5484.
15. Post SM, Quintas-Cardama A, Pant V etal. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010; 18: 220-230.
16. Ohmiya N, Taguchi A, Mabuchi N etal. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol. 2006; 24: 4434-4440.
17. Heist RS, Zhou W, Chirieac LR etal. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J. Clin. Oncol. 2007; 25: 2243-2247.
18. Asomaning K, Reid AE, Zhou W etal. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin. Cancer Res. 2008; 14: 4010-4015.
19. Cescon DW, Bradbury PA, Asomaning K etal. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin. Cancer Res. 2009; 15: 3103-3109.
20. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006; 25: 1602-1611.
21. Jiang DK, Yao L, Wang WZ etal. TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis. World J. Gastroenterol. 2011; 17: 1227-1233.
22. Gottschlich S, Maune S, Preugschat J etal. P53 analysis of laryngeal cancer in exon 4 to 9. Anticancer Res. 2000; 20: 2613-2616.
23. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002; 183: 123-130.
24. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin. Cancer Res. 2004; 10: 5845-5849.
25. Sullivan A, Syed N, Gasco M etal. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-3337.
26. Biros E, Kohut A, Biros I, Kalina I, Bogyiova E, Stubna J. A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. Lung Cancer 2002; 35: 231-235.
27. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005; 26: 1770-1773.
28. Tommiska J, Eerola H, Heinonen M etal. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 2005; 11: 5098-5103.
29. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. Cancer 2010; 10: 87-101.
30. Anderson LA, Cantwell MM, Watson RG etal. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009; 136: 799-805.
31. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma-a population-based cohort study. Am. J. Gastroenterol. 2006; 101: 1193-1199.
32. Zhai R, Chen F, Liu G etal. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J. Clin. Oncol. 2010; 28: 2445-2451.
33. Ueda M, Yamamoto M, Nunobiki O etal. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum. Cell 2009; 22: 49-54.
34. Onat OE, Tez M, Ozcelik T, Toruner GA. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res. 2006; 26: 3473-3475.